Trial Profile
A Phase I, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD0156 Monotherapy or in Combination With Either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients With Advanced Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Sep 2022
Price :
$35
*
At a glance
- Drugs AZD 0156 (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Olaparib
- Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Solid tumours
- Focus Adverse reactions
- Acronyms AToM
- Sponsors AstraZeneca
- 16 Sep 2022 Status changed from active, no longer recruiting to completed.
- 08 Nov 2021 Planned End Date changed from 13 Sep 2022 to 7 Nov 2022.
- 17 Aug 2021 Planned End Date changed from 13 Sep 2021 to 13 Sep 2022.